Literature DB >> 2340850

Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection.

C Mallo1, R Zaĭdan, G Galy, E Vermeulen, J Brun, G Chazot, B Claustrat.   

Abstract

The pharmacokinetics of melatonin during the day-time has been studied in 4 healthy subjects after a bolus i.v. injection of 5 or 10 micrograms/person and after a 5 h infusion of 20 micrograms per person in 6 healthy subjects. In addition, a pinealomectomized patient whose nocturnal plasma melatonin had been abolished was investigated after the i.v. infusion--once during the night and once during the day. The clearance of melatonin from blood showed a biexponential decay. The pharmacokinetic parameters in the two studies were similar, except for the disappearance rate constant beta and the apparent volume of distribution at steady-state (Vss). Supplementary peaks or troughs were superimposed on the plateau and the falling part of the profile. They were not due to stimulation of endogenous secretion, because they were also seen in the pinealomectomized patient. During the melatonin infusion, the plasma hormone level reached a steady-state after 60 and 120 min, and when it was equal to the nocturnal level. The infusion regime may be valuable in replacing blunted hormonal secretion in disease states.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2340850     DOI: 10.1007/bf00315035

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Nocturnal plasma melatonin levels in migraine: a preliminary report.

Authors:  B Claustrat; C Loisy; J Brun; S Beorchia; J L Arnaud; G Chazot
Journal:  Headache       Date:  1989-04       Impact factor: 5.887

2.  Periodicity during the distributive phase for drugs administered intravenously to humans.

Authors:  J H Wood; A J Lee; L K Garrettson
Journal:  Drug Metab Rev       Date:  1979       Impact factor: 4.518

3.  Plasma concentrations of melatonin in man following oral absorption of different preparations.

Authors:  M Aldhous; C Franey; J Wright; J Arendt
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

4.  Oral administration and distribution of melatonin in human serum, saliva and urine.

Authors:  O Vakkuri; J Leppäluoto; A Kauppila
Journal:  Life Sci       Date:  1985-08-05       Impact factor: 5.037

5.  Pharmacokinetics of melatonin in man: first pass hepatic metabolism.

Authors:  E A Lane; H B Moss
Journal:  J Clin Endocrinol Metab       Date:  1985-12       Impact factor: 5.958

6.  A comparison of two methods for detecting hormone peaks: the effect of sampling interval on gonadotropin peak frequency.

Authors:  J L Ross; K M Barnes; S Brody; G R Merriam; D L Loriaux; G B Cutler
Journal:  J Clin Endocrinol Metab       Date:  1984-12       Impact factor: 5.958

7.  Melatonin serum levels and metabolic clearance rate in patients with liver cirrhosis.

Authors:  H Iguchi; K I Kato; H Ibayashi
Journal:  J Clin Endocrinol Metab       Date:  1982-05       Impact factor: 5.958

8.  A chronobiological study of melatonin, cortisol growth hormone and prolactin secretion in cluster headache.

Authors:  G Chazot; B Claustrat; J Brun; D Jordan; G Sassolas; B Schott
Journal:  Cephalalgia       Date:  1984-12       Impact factor: 6.292

9.  A chronobiological study of melatonin and cortisol secretion in depressed subjects: plasma melatonin, a biochemical marker in major depression.

Authors:  B Claustrat; G Chazot; J Brun; D Jordan; G Sassolas
Journal:  Biol Psychiatry       Date:  1984-08       Impact factor: 13.382

10.  Bioavailability of oral melatonin in humans.

Authors:  F Waldhauser; M Waldhauser; H R Lieberman; M H Deng; H J Lynch; R J Wurtman
Journal:  Neuroendocrinology       Date:  1984-10       Impact factor: 4.914

  10 in total
  20 in total

1.  Inhibition of melatonin biosynthesis induces neurofilament hyperphosphorylation with activation of cyclin-dependent kinase 5.

Authors:  Shaohui Wang; Lingqiang Zhu; Hairong Shi; Hongyun Zheng; Qing Tian; Qun Wang; Rong Liu; Jian-Zhi Wang
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 3.996

Review 2.  Influence of melatonin and photoperiod on animal and human reproduction.

Authors:  A Cagnacci; A Volpe
Journal:  J Endocrinol Invest       Date:  1996-06       Impact factor: 4.256

Review 3.  Clinical pharmacokinetics of melatonin: a systematic review.

Authors:  Nathja Groth Harpsøe; Lars Peter Holst Andersen; Ismail Gögenur; Jacob Rosenberg
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

4.  Sleep and inflammatory bowel disease: exploring the relationship between sleep disturbances and inflammation.

Authors:  Jami A Kinnucan; David T Rubin; Tauseef Ali
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-11

5.  Melatonin Delivery: Transdermal and Transbuccal Evaluation in Different Vehicles.

Authors:  Ana Flo; Ana C Calpena; Lyda Halbaut; Erika I Araya; Francisco Fernández; Beatriz Clares
Journal:  Pharm Res       Date:  2016-03-08       Impact factor: 4.200

Review 6.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

7.  Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans.

Authors:  D J Skene; C J Bojkowski; J Arendt
Journal:  Br J Clin Pharmacol       Date:  1994-02       Impact factor: 4.335

Review 8.  Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature.

Authors:  Esmée M S Vural; Barbara C van Munster; Sophia E de Rooij
Journal:  Drugs Aging       Date:  2014-06       Impact factor: 3.923

Review 9.  Melatonin: possible implications for the postoperative and critically ill patient.

Authors:  Richard S Bourne; Gary H Mills
Journal:  Intensive Care Med       Date:  2006-02-14       Impact factor: 17.440

10.  Neuroprotective effects of high-dose vs low-dose melatonin after blunt sciatic nerve injury.

Authors:  Ghaffar Shokouhi; R Shane Tubbs; Mohammadali M Shoja; Shahram Hadidchi; Amir Ghorbanihaghjo; Leila Roshangar; Ramin M Farahani; Mehran Mesgari; W Jerry Oakes
Journal:  Childs Nerv Syst       Date:  2007-05-15       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.